Cost–effectiveness of lanreotide Autogel^® in treatment algorithms of acromegaly

References

• Melmed S. Medical progress: acromegaly. N. Engl. J. Med.355(24), 2558–2573 (2006).
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Romijn JA, Pereira AM, Roelfsema F. Current pharmacotherapy for acromegaly: a review. Expert Opin. Pharmacother.6(14), 2393–2405 (2005).
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Dekker FW, Pereira AM et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J. Clin. Endocrinol. Metab.89(6), 2789–2796 (2004).
   PubMed Web of Science ®Google Scholar
• Melmed S, Casanueva F, Cavagnini F et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol.153(6), 737–740 (2005).
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev.25(1), 102–152 (2004).
   PubMed Web of Science ®Google Scholar
• Pereira AM, van Thiel SW, Lindner JR et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab.89(1), 71–75 (2004).
   PubMed Web of Science ®Google Scholar
• Giustina A, Barkan A, Casanueva FF et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab.85(2), 526–529 (2000).
   PubMed Web of Science ®Google Scholar
• Melmed S, Colao A, Barkan A et al. Guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. (2009) (Epub ahead of print).
   Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J. Clin. Endocrinol. Metab.93(1), 61–67 (2008).
   PubMed Web of Science ®Google Scholar
• Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur. J. Endocrinol.152(3), 379–387 (2005).
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J. Clin. Endocrinol. Metab.85(7), 2476–2482 (2000).
   PubMed Web of Science ®Google Scholar
• Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J. Clin. Endocrinol. Metab.85(12), 4596–4602 (2000).
   PubMed Web of Science ®Google Scholar
• Attanasio R, Epaminonda P, Motti E et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J. Clin. Endocrinol. Metab.88(7), 3105–3112 (2003).
   PubMed Web of Science ®Google Scholar
• Castinetti F, Morange I, Dufour H, Regis J, Brue T. Radiotherapy and radiosurgery in acromegaly. Pituitary12(1), 3–10 (2009).
   PubMed Web of Science ®Google Scholar
• Castinetti F, Taieb D, Kuhn JM et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion J. Clin. Endocrinol. Metab.90(8), 4483–4488 (2005).
   PubMed Web of Science ®Google Scholar
• Gutt B, Wowra B, Alexandrov R et al. Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly. Exp.Clin. Endocrinol. Diabetes113(4), 219–224 (2005).
   PubMed Web of Science ®Google Scholar
• Landolt AM, Haller D, Lomax N et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J. Neurosurg.88(6), 1002–1008 (1998).
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet358(9295), 1754–1759 (2001).
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med.342(16), 1171–1177 (2000).
   PubMed Web of Science ®Google Scholar
• Feenstra J, de Herder WW, ten Have SM et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet365 (9471), 1644–1646 (2005).
   PubMed Web of Science ®Google Scholar
• Abs R, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab.83(2), 374–378 (1998).
   PubMed Web of Science ®Google Scholar
• Antonijoan RM, Barbanoj MJ, Cordero JA et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J. Pharm. Pharmacol.56(4), 471–476 (2004).
   PubMed Web of Science ®Google Scholar
• Kuhn JM, Legrand A, Ruiz JM, Obach R, De Ronzan J, Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br. J. Clin. Pharmacol.38(3), 213–219 (1994).
   PubMed Web of Science ®Google Scholar
• Astruc B, Marbach P, Bouterfa H et al. Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles. J. Clin. Pharmacol.45(7), 836–844 (2005).
   PubMed Web of Science ®Google Scholar
• Bronstein M, Musolino N, Jallad R et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin. Endocrinol. (Oxf.)63(5), 514–519 (2005).
   PubMed Web of Science ®Google Scholar
• Grass P, Marbach P, Bruns C, Lancranjan I. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships Metabolism45(8 Suppl. 1), 27–30 (1996).
   PubMed Web of Science ®Google Scholar
• Caron P. Somatuline® Autogel®, a new formulation of lanreotide for the treatment of acromegalic patients. Ann. Endocrinol. (Paris)63(2 Pt 3), 2S19–2S24 (2002).
   PubMedGoogle Scholar
• van Thiel SW, Romijn JA, Biermasz NR et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur. J. Endocrinol.150(4), 489–495 (2004).
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Abrams P, Verhelst J et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur. J. Endocrinol.151(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Ashwell SG, Bevan JS, Edwards OM et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur. J. Endocrinol.150(4), 473–480 (2004).
   PubMed Web of Science ®Google Scholar
• Caron P, Bex M, Cullen DR et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin. Endocrinol. (Oxf.)60(6), 734–740 (2004).
   PubMed Web of Science ®Google Scholar
• Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (lanreotide Autogel). Exp. Clin. Endocrinol. Diabetes113(3), 139–144 (2005).
   PubMed Web of Science ®Google Scholar
• Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin. Endocrinol. (Oxf.)64(2), 209–214 (2006).
   PubMed Web of Science ®Google Scholar
• Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a Phase III trial. Clin. Endocrinol. (Oxf.)65(3), 320–326 (2006).
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Boschetti M, Degli Uberti EC et al. Efficacy of a slow-release formulation of lanreotide (Autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin. Endocrinol. (Oxf.)67(4), 512–519 (2007).
   PubMed Web of Science ®Google Scholar
• Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin. Endocrinol. (Oxf.)68(3), 473–480 (2008).
   PubMed Web of Science ®Google Scholar
• Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin. Endocrinol. (Oxf.)69(2), 299–305 (2008).
   PubMed Web of Science ®Google Scholar
• Attanasio R, Lanzi R, Losa M et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr. Pract.14(7), 846–855 (2008).
   PubMedGoogle Scholar
• Melmed S, Sternberg R, Cook D et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J. Clin. Endocrinol. Metab.90(7), 4405–4410 (2005).
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab.90(8), 4465–4473 (2005).
   PubMed Web of Science ®Google Scholar
• Roelfsema F, Biermasz NR, Pereira AM, and Romijn JA. Therapeutic options in the management of acromegaly: focus on lanreotide Autogel. Biologics: Targets Ther.2(3), 463–479 (2008)
   PubMedGoogle Scholar
• Pereira AM, Biermasz NR, Roelfsema F, Romijn JA. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat. Endocrinol.4(1), 43–53 (2005).
   PubMedGoogle Scholar
• Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J. Effects of the long-acting somatostatin analogue lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur. J. Endocrinol.155(1), 73–78 (2006).
   PubMed Web of Science ®Google Scholar
• Ertorer ME, Bakiner O, Anaforoglu I, Bozkirli E, Tutuncu NB, Demirag NG. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. Neuro. Endocrinol. Lett.28(6), 727–733 (2007).
   PubMed Web of Science ®Google Scholar
• Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a meta-analysis of acromegaly studies. J. Clin. Endocrinol. Metab. (2009) (Epub ahead of print).
   Google Scholar
• Colao A, Marek J, Goth MI et al. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J. Clin. Endocrinol. Metab.93(6), 2243–2248 (2008).
   PubMed Web of Science ®Google Scholar
• Trepp R, Everts R, Stettler C et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin. Endocrinol. (Oxf.)63(1), 103–110 (2005).
   PubMed Web of Science ®Google Scholar
• Paisley AN, Rowles SV, Roberts ME et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin. Endocrinol. (Oxf.)67(3), 358–362 (2007).
   PubMed Web of Science ®Google Scholar
• Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur. J. Endocrinol.158(3), 305–310 (2008).
   PubMed Web of Science ®Google Scholar
• Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J. Clin. Endocrinol. Metab.90(6), 3337–3341 (2005).
   PubMed Web of Science ®Google Scholar
• Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur. J. Endocrinol.155(6), 831–837 (2006).
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab.92(12), 4598–4601 (2007).
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, de Herder WW et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab.93(10), 3853–3859 (2008).
   PubMed Web of Science ®Google Scholar
• Caron P, Beckers A, Cullen DR et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J. Clin. Endocrinol. Metab.87(1), 99–104 (2002).
   PubMed Web of Science ®Google Scholar
• van Thiel SW, Romijn JA, Biermasz NR et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur. J. Endocrinol.150(4), 489–495 (2004).
   PubMed Web of Science ®Google Scholar
• Didoni G, Grottol S, Gasco V et al. Cost-of-illness study in acromegalic patients in Italy. J. Endocrinol. Invest.27(11), 1034–1039 (2004).
   PubMed Web of Science ®Google Scholar
• Luque-Ramirez M, Paramo C, Varela DC, Garcia-Mayor RV. Cost of management of invasive growth hormone-secreting macroadenoma. J. Endocrinol. Invest.30(7), 541–545 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson LS, Shin JL, Ezzat S. Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr. Pract.7(3), 170–180 (2001).
   PubMedGoogle Scholar
• Knutzen R, Ezzat S. The cost of medical care for the acromegalic patient. Neuroendocrinology83(3–4), 139–144 (2006).
   PubMed Web of Science ®Google Scholar
• Valentim J, Passos V, Mataveli F, Calabro A. Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil. Arq. Bras. Endocrinol. Metabol.52(9), 1452–1460 (2008).
   PubMedGoogle Scholar
• Biermasz NR, van den Oever NC, Frolich M et al. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf.)58(3), 288–295 (2003).
   PubMed Web of Science ®Google Scholar
• Turner HE, Thornton-Jones VA, Wass JA. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin. Endocrinol. (Oxf.)61(2), 224–231 (2004).
   PubMed Web of Science ®Google Scholar
• Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur. J. Endocrinol.157(5), 571–577 (2007).
   PubMed Web of Science ®Google Scholar
• Bevan JS, Newell-Price J, Wass JA et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin. Endocrinol. (Oxf.)68(3), 343–349 (2008).
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Rizzo E, Lania AG et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur. J. Endocrinol.158(1), 19–25 (2008).
   PubMed Web of Science ®Google Scholar
• van der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA. Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol (Oxf.)69(1), 123–128 (2008).
   PubMed Web of Science ®Google Scholar